Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Active, not recruiting · Phase 2 · NCT04430179
Conditions: Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
At a glance
- Research payments reported, 2025
- $2,864
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- University of South Florida
- Tested
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] (drug), Placebo (other)
- Dates
- Started 2020-12-17; completion 2025-07
- Results posted
- Not yet
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score \>=10 at baseline.
From ClinicalTrials.gov, last updated 2025-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $2,864 in research payments for this study in 2025 (2 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of South Florida Board of Trustees $2,864
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.